BITFLYER
30.9.2020 06:02:05 CEST | Business Wire | Press release
Leading cryptocurrency exchange bitFlyer has announced the launch of cross-border trading on its platform. For the first time, users in Europe will be able to access one of the largest bitcoin markets in Japan, while still using a European-regulated platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200929005920/en/
The Japanese bitcoin market is one of the biggest in the world, with approximately 20%1 of the global BTC to FIAT (national currencies) trading volume being traded against the JPY. As Japan’s leading exchange, more than 70%2 of the JPY trading volume passes through the bitFlyer platform. This makes the launch of cross-border trading a natural next step for bitFlyer in consolidating its position as a global player.
bitFlyer is now not only the first cryptocurrency exchange that is licensed to operate in Japan, the EU, and the US combined, but is also the first to facilitate this cross-border access to its prized JPY liquidity.
Cross-border trading is of particular benefit to traders looking to handle large volumes, as the increased liquidity will allow for faster execution of trades, reducing the risk of slippage and the spread between buy and sell prices.
Andy Bryant, COO of bitFlyer Europe, said , “The launch of bitFlyer’s cross-border trading is revolutionary for the cryptocurrency industry and a huge milestone for us. Before now, it’s been virtually impossible for traders with Euros to participate in the BTC/JPY trading pair without going through multiple extra steps and/or sign up processes, bringing unwanted inconvenience and delays.
“bitFlyer is quite simply giving more of its users an unprecedented opportunity to trade in one of the largest and most liquid markets in the world. Those more experienced and successful traders will know just how important it is to seek the most liquid markets, and we’re confident with this launch we can offer a better experience for them and all our users”.
Until now, cross-border trading has posed challenges to traders as it is extremely difficult for overseas users to sign up to Japanese exchanges. bitFlyer’s cross-border trading initiative enables users to access BTC/JPY under their existing bitFlyer Europe account, without the need to open multiple accounts across multiple exchange platforms.
bitFlyer’s long-term objective is to have all spot trading pairs available across all regions, including BTC/JPY in the US, BTC/USD in Europe and Japan, and BTC/EUR in Japan and the US.
Users trading BTC/JPY via bitFlyer Europe will still be subject to the same European privacy policies and their rights will not be affected. All bitFlyer entities are regulated to the highest standards according to their jurisdictions, meaning proper controls and compliance with local AML and KYC laws.
“bitFlyer’s objective has always been to create a truly global cryptocurrency trading platform that allows users to benefit from the scale, depth and liquidity of one, single marketplace. Liquidity is a constant challenge for cryptocurrency markets and is essential to ensure the future growth and sustainability of BTC and the cryptocurrency industry as a whole. Today’s announcement is a huge step forward in that regard” says Yuzo Kano, Founder of bitFlyer group and Chairman of bitFlyer Europe.
bitFlyer Europe launched in January 2018 as a fully owned subsidiary of bitFlyer, Inc., a household name in the cryptocurrency space in Japan, and one of the longest-standing cryptocurrency exchanges. bitFlyer is the only cryptocurrency exchange to be licenced in Japan, the US and Europe combined, and has also recently been recognised as one of only 10 exchanges3 that isn’t faking trading volumes.
ENDS
About bitFlyer Europe S.A.
bitFlyer Europe S.A. is a wholly-owned subsidiary of bitFlyer, Inc., a leading bitcoin and blockchain company based in Japan. The European office is located in Luxembourg and operates an exchange platform for European traders to buy and sell virtual currencies. bitFlyer Europe S.A. site: https://bitflyer.com/en-eu/
1 https://www.coinhills.com/market/currency/
2 https://jpbitcoin.com/market/volume
3 https://www.sec.gov/comments/sr-nysearca-2019-01/srnysearca201901-5164833-183434.pdf
View source version on businesswire.com: https://www.businesswire.com/news/home/20200929005920/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TACTICAAI and NVIDIA Collaborate to Scale Agentic AI Capabilities with NVIDIA Nemotron22.10.2026 12:01:00 CEST | Press release
Collaboration brings together TACTICAAI’s operational decision-intelligence technology and NVIDIA AI capabilities to advance reasoning, autonomous analysis and video intelligence for real-world deployment TACTICAAI, an operational decision-intelligence company, today announced a collaboration with NVIDIA to advance and scale the deployment of agentic AI capabilities. The companies will work together to integrate and optimize NVIDIA Nemotron models within TACTICAAI’s multi-intelligence platform, with a focus on expanding these capabilities and supporting deployment with major customers internationally. The collaboration was announced at NVIDIA GTC Berlin. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022054475/en/ TACTICA AI and NVIDIA Collaborate to Scale Agentic AI Capabilities with NVIDIA Nemotron (Graphic: AETOSWire) The collaboration with NVIDIA builds on the company’s existing technology, integrating selected NVIDIA
BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 522.10.2026 12:01:00 CEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its third quarter 2026 financial results on Thursday, November 5, 2026, before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com.To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has
Bregal Milestone Backs Nethive With Majority Growth Investment and JoyComm Acquisition22.10.2026 10:00:00 CEST | Press release
Partnership to support Nethive’s next phase of growth as a leading cybersecurity services and software platform Bregal Milestone, a leading European software growth private equity firm, today announced a majority growth investment in Nethive S.p.A. (“Nethive” or the “Company”), a leading Italian cybersecurity services and software provider. Alongside its investment in Nethive, Bregal Milestone has also backed Nethive’s acquisition of IT security specialist Joy Comm S.r.l. (“JoyComm”). Founded in 2014 by Alessandro Bellato and Diego Rocco, Nethive has become a trusted cybersecurity partner to blue-chip enterprises, SMEs, and public-sector organizations across Italy. Its platform spans managed security services, professional services and technology resale, helping organizations protect critical infrastructure and networks, strengthen cyber resilience and reduce operational complexity. Nethive combines deep technical expertise with 24/7 monitoring, threat detection and response, risk and
EOS and VOP CZ Sign Memorandum of Understanding to Explore Cooperation on Czech Programmes22.10.2026 09:00:00 CEST | Press release
EOS Defence Systems (EOS) and VOP CZ have signed a Memorandum of Understanding (MoU) at Future Forces Forum in Prague to explore cooperation on wheeled armoured vehicle programmes for the Czech Army and other future defence projects in the Czech Republic and Europe where VOP CZ is involved. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021408045/en/ EOS and VOP CZ sign a Memorandum of Understanding at Future Forces Forum in Prague. Left to right: Martin van de Voorde, Sales Director Europe, EOS; Vlastimil Navrátil, Managing Director, VOP CZ; Pavla Ungrová, Sales Director, VOP CZ; Rear Admiral Richard Caton, Australia’s Military Representative to NATO and the EU; Group Captain Michael Schleeman, Australia’s Defence Attaché; and Matej Pupák, Program Lead, VOP CZ. The agreement brings together EOS' expertise in advanced remote weapon systems (RWS) with VOP CZ's established capabilities in military vehicle integration, produ
Ferrer and Prilenia Announce Authorization for EU Initiation of Confirmatory PRECISE-HD Study of Pridopidine in Huntington's Disease22.10.2026 09:00:00 CEST | Press release
Ferreri and Prilenia Therapeutics B.V.today announced that the confirmatory Phase 3 PRECISE-HD study of investigational pridopidine in Huntington's disease (HD) has received authorization to begin in participating EU Member States (EU CT number: 2026-526093-16-00, NCT07609108). Recruitment in the EU is expected to commence this month, joining currently recruiting sites in the US and UK, with Canada to follow. Designed to evaluate the efficacy and safety of pridopidine (administered as an oral capsule twice a day), and to generate data for regulatory evaluation, the global, approximately 400-participant, randomized, double-blind, placebo-controlled PRECISE-HD study will assess the clinical effect of the investigational treatment on disease progression, functional capacity, motor function, cognition, speech and quality of life. “The initiation of PRECISE-HD in Europe marks a milestone for the Huntington’s disease research community. This confirmatory Phase 3 study has been designed to bu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
